Nuvectis Pharma, Inc. (NVCT) Stock Price & Growth Analysis

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

Nuvectis Pharma, Inc.

NVCT

NASDAQ

Unprofitable

168M

Biotechnology

Next Earning date - 05 Aug 2025

168M

Biotechnology

Next Earning date - 05 Aug 2025

8.05USD

-0.06 ( -0.68%)

Market Open

Relative Strenght

Volume Buzz

-39%

Earning Acce

Dist 52w H.

32%

Overview Chart

Quote Panel

Updated June 18, 2025

1W -8.49 % 1M -26.21 % 3M -9.82 % 1Y 18.30 %

Key Metrics

Market Cap
168.30M
Shares Outstanding
20.89M
Share in Float
10.76M
Dividende
0

Earning Date
05 Aug 2025
Price Target
8.055
Average Volume
133655
Beta
-0.163

Range
4.44-11.8
Industry
Biotechnology
Website
https://www.nuvectis.com
Sector
Healthcare

Quote Panel

Updated June 18, 2025

1W % 1M % 3M % 1Y %

Key Metrics

Market Cap
Shares Outstanding
Share in Float
Dividende

Earning Date
No Data
Price Target
Average Volume
Beta

Range
Industry
Website
Sector

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

7.72x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-1.1

EPS

How NVCT compares to sector?

P/E Ratio

Fundamentals

Relative Strength

NVCT

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Relative Strength

NVCT

Sector

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$3M

NaN%

2026-Revenue

$1.07

-297%

2026-EPS

$2M

132%

2026-EBITDA

Analyst rating

Strong Sell

Sell

Buy

Neutral

Strong Buy

Buy

Price Target

NaN(-100.00%)

Number of analyst

Last analyst upgrade/downgrade

No Data Available

Forecast

Analyst rating

Last analyst upgrade/downgrade

Earnings Growth

YoY

Current

Estimates

Q2.23

N/A

-0.38
vs -0.28

Q3.23

N/A

-0.37
vs -0.42

Q4.23

N/A

-0.41
vs -0.48

Q1.24

N/A

-0.25
vs -0.27

Q2.24

N/A

-0.26
vs -0.38

Q3.24

N/A

-0.24
vs -0.37

Q4.24

N/A

-0.36
vs -0.41

Q1.25

N/A

-0.27
vs -0.25

Q2.25

N/A

-0.25
vs -0.26

Q3.25

N/A

-0.26
vs -0.24

Sales Growth

YoY

Current

Estimates

Q4.22

+3625%

149K vs 4K

Q1.23

4.1M vs NA

Q2.23

NA vs NA

Q3.23

NA vs NA

Q4.23

-2852%

-4101000.00 vs 149K

Q1.24

-100%

NA vs 4.1M

Q2.24

NA vs NA

Q3.24

NA vs NA

Q4.24

+100%

NA vs -4101000

Q1.25

NA vs NA

Return on Equity

QoQ

Q2.23

-28%

-0.28
vs -0.33

Q3.23

-35%

-0.35
vs -0.28

Q4.23

-54%

-0.54
vs -0.35

Q1.24

-30%

-0.30
vs -0.54

Q2.24

-35%

-0.35
vs -0.30

Q3.24

-38%

-0.38
vs -0.35

Q4.24

-64%

-0.64
vs -0.38

Q1.25

-25%

-0.25
vs -0.64

Institutionnal Ownership

QoQ

Q2.23

37
vs 13

185%

Q3.23

33
vs 37

-11%

Q4.23

36
vs 33

Q1.24

40
vs 36

11%

Q2.24

39
vs 40

-2%

Q3.24

31
vs 39

-21%

Q4.24

31
vs 31

Q1.25

37
vs 31

19%

Earnings Growth

Latest News

globenewswire.com

8 hours ago

Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights

globenewswire.com

8 hours ago

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

businesswire.com

8 hours ago

Market News Alert: Nuvectis Pharma's NXP900 Demonstrates Superior Efficacy in NSCLC When Combined with Tagrisso in Cleveland Clinic Study, Following New Buy Recommendation

zacks.com

11 hours ago

Does Nuvectis Pharma (NVCT) Have the Potential to Rally 108.79% as Wall Street Analysts Expect?

globenewswire.com

16 hours ago

Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

globenewswire.com

16 hours ago

Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting

Company Description

8.05USD

N/A

0.00x

7.72x

0.0

0.0%

$-1.1

$3M

$1.07

$2M

Earnings Growth

Latest News

$3M

$1.07

$2M

Company Description

8.05USD

N/A

0.00x

7.72x

0.0

0.0%

$-1.1